Aclaris Therapeutics, Inc. (ACRS): Kamil Ali-jackson , Chief Legal Officer of Aclaris Therapeutics, Inc. sold 1,841 shares on Sep 28, 2016. The Insider selling transaction was reported by the company on Sep 28, 2016 to the Securities and Exchange Commission. The shares were sold at $24.66 per share for a total value of $45,399.06 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 29, 2016, Kamil Ali-jackson (Chief Legal Officer) sold 3,738 shares at $20.35 per share price.On Oct 14, 2015, Llc Fmr (10% owner other) purchased 335,455 shares at $11.00 per share price.Also, On Oct 13, 2015, Albert Cha (director) purchased 454,545 shares at $11.00 per share price.On Oct 13, 2015, Anand Mehra (director 10% owner) purchased 409,090 shares at $11.00 per share price.
Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.